Table 4
Selected treatment-related nonneoplastic lesions of liver and thyroid in male and female rats and mice.

Dana (ma (h.)			0				F0
Dose (mg/kg)	0		3		15		50
Male rat Liver	49		50		50		50
Numbered	.,				50		
examined							
Hepatocyte	1 (29			(88%)**		(100%)**	50(100 %)**
hypertrophy	[1.0]		[2.1		[3.		[3.8]
Basophilic focus Clear cell focus	16(3:			42%) (74%)		(22% (70%)	11(22%) 29 (58%)*
Eosinophilic focus	39 (80%)** 3 (6%)**		37 (74%) 3 (6%)			(24%)*	15 (30%)**
Hyperplasia, nodular	0		0		3	(2170)	0
Fatty change	32 (65%)**		37 (74%)		48	(96%)**	48 (96%)**
Cholangiofibrosis	0		0			2%)	1 (2%)
Inflammation chronic	1 (2%)* 0 **		2 (4%)		0		5 (10%)
Pigmentation Oval cell hyperplasia	0 **		0			2%)	6 (12%)* 3 (6%)
Thyroid,	0 ^ 45		45		2 (4%) 48		46
Number	10		10		10		10
examined							
Thyroid gland follicle	1**(2	2%)	26**(58%)		34**(70%)		23**(50%)
hypertrophy	[1.2]		[1.4	1]	[2.	0]	[2.4]
Female Rat							
Liver	50		49		50		47
Number							
examined			40	(000():		(1000/311	4F (050/211
Hepatocyte	0 **		48 (98%)**			(100%)**	45 (96%)** [3.9]
hypertrophy Basophilic focus	44 (88%)		[1.9] 43 (88%)		[3. 40	(80%)	[3.9]
Clear cell focus	35 (70%)		21 (43%)		26 (52%)		31 (66%)
Eosinophilic focus	5 (10%)**		7 (14%)		21 (42%)**		31 (66%)**
Fatty change	15 (30%)**		12 (24%)		28	(56%)**	39 (83%)**
Cholangiofibrosis	0 **		0		0		3 (6%)
Hyperplasia, nodular	0 **		0		2 (4%)		7 (15%)**
Hepatocyte Necrosis Bile duct cyst	4 (8%)*		2 (4%) 2 (4%)		1 (2%) 5 (10%)		8 (17%) 7 (15%)*
Oval cell hyperplasia	2 (4%)* 1 (2%)		3 (6%)		3 (6%)		10 (21%)**
Uterus	50		50		50		49
Numbered							
examined							
Vaginal polyp	0		0		0		1(2%)
Uterus histiocytic sarcoma	0*		0		0		2(4%)
Uterus metaplasia	0**		0		10	2%)	4(8%)*
Cervix Hyperplasia	0*			0		-70)	2 (4%)
Thyroid, Number	45		49		47		42
examined							
Thyroid gland	8(16%)**		17 (34%)		22**(47%)		35**(83%)
Follicle	[1.1		[1.3]		[1,4]		[1.9]
hypertrophy							
Dose (mg/kg)		0		3		30	100
Male mouse							
Liver		50		49		50	49
Number examined		-				-	
Centrilobular, hepatocy	te,	0**		28(56%)	**	46(92%)**	48(96%)**
hypertrophy				[1.6]		[3.8]	[3.9]
atty change		17(34%) 2(4%)*)	25(50%)		17(34%)	5(10%)
Necrosis, focal			rskr	2(4%) 15(305)*		16(32%)** 33(66%)**	2(4%) 25(50%)**
Kupffer cell pigmentation Clear cell focus		5(10%) ³		13(305)		20*	25(50%)*** 7
Thyroid							•
Number examined							
Thyroid gland Follicle,		25**		35*		41*	45*
hypertrophy		[1.3]		[1.5]		[1.5]	[2.4]
Female mouse							
		50		49		50	49
Number examined		0++		FICT 4012		45(0000000	47/0/02/
Centrilobular hypertrophy		0**		7(14%)**		45(90%)**	47(96%)**
Eosinophilic focus		3(6%)**		[1.0] 2(4%)		[2.0] 16(325)**	[3.6] 15(31%)**
Fatty change		18(36%)**		2(4%) 18(37%)		39(78%)**	20(41%)*
		4(8%)*		1(2%)		4(8%)	5(10%)
Hemorrhage		4(80%)*		1(2%)		4(8%)	5(10%)

Table 4 (continued)

Dose (mg/kg)	0	3	30	100
Necrosis, focal Kupffer cell pigmentation Thyroid gland	1(2%)* 3(6%)** 50	1(2%) 10(20%)* 49	4(8%) 24(48%)** 48	3(6%) 27(55%)** 47
Number examined Thyroid gland	24	31	37**	42**
Follicle, hypertrophy	[1.3]	[1.5]	[1.5]	[2.4]

 $^{^{\}rm a}$ Average severity greade of lesions in affected animals: 1 = minimal, $2^{\rm -mild}$,

^{3 =} moderate, 4 = marked.